Akamine Scott 4

What Happened

• Scott Akamine, Chief Legal Officer of Kailera Therapeutics (KLRA), was granted two derivative awards on April 16, 2026: 60,000 shares and 60,000 shares (total 120,000) reported at $0.00 (these are option/award grants, not open-market purchases or sales).
• The filings show acquisition of 60,000 + 60,000 derivative shares; no immediate cash transaction or sale occurred.

Key Details

• Transaction date: April 16, 2026; Filing date: April 20, 2026 (filed 4 days after the transaction; Form 4 is normally due within 2 business days, so this appears late).
• Reported price: $0.00 for each award entry (derivative/option awards are commonly reported this way).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote F1 (first 60,000): Time-based vesting — 25% vests on April 16, 2027, then the remainder vests in 36 substantially equal monthly installments, subject to continued service.
• Footnote F2 (second 60,000): Performance-based vesting — vests in full only if (i) the average daily closing price on Nasdaq over any 30 consecutive calendar-day period between Oct 16, 2026 and Apr 16, 2030, or (ii) the stock price in a change-in-control during that period, equals or exceeds $40 per share, and subject to continued service.

Context

• These entries are grants of equity awards (derivatives/options). They are not purchases or sales and do not indicate an immediate change in share ownership or a market transaction.
• The time-based award vests gradually with continued employment; the second award vests only if a substantial stock-price performance hurdle ($40) is met during the specified measurement window — a conditional, potentially value-generating award for the executive.